Few large biotech stocks have rewarded patience like Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the size of that run ...

The average one-year price target for Moderna (BMV:MRNA) has been revised to MX$2,205.98 / share. This is an increase of 13.03% from the prior estimate of MX$1,951.61 dated September 13, 2026. These ...

Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has ...

Moderna Inc MRNA shares are trending Thursday as the stock continues working through volatility following a bearish Citi ...

Citi analyst says Moderna stock could crash as much as 60% from here. Here’s why he issued a bearish note on MRNA shares ...

Moderna (MRNA) stock rose after confirming Nasdaq-100 inclusion, even as Citi downgrades the stock on valuation concerns.

According to Nasdaq on October 1, 2026, Moderna will become a Nasdaq-100 component before market open on October 9, replacing ...

Moderna stock was at EUR 168.97 after-hours at 8:28 p.m. CEST on October 6, 2026. The price was minus 6.49 percent versus the ...

Moderna stock MRNA fell nearly 6% in premarket trading on Wednesday after Citi downgraded the biotech company to ‘Sell’ from ...

Moderna stock has delivered a very large 1 year gain, yet the company still screens as expensive on broad valuation checks. After that kind of move, the question for investors is whether the current ...

Moderna (MRNA +2.08%) soared onto the scene in early pandemic days with its messenger RNA technology and delivered a coronavirus vaccine in a matter of months. As the vaccine brought in blockbuster ...

Nasdaq-100 entry creates forced, short-term index demand, but Citi’s core point is still the thesis killer: valuation is stretched versus realistic oncology sales. The stock is already up 500% in 2026 ...